{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:21:35Z","timestamp":1794471695295,"version":"4.9.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as the Common Terminology Criteria for Adverse Events (CTCAE), neither reflect the unique quality of post\u2013CAR-T neutrophil recovery, nor do they reflect the inherent risk of infections due to protracted neutropenia. For this reason, a novel EHA\/EBMT consensus grading was recently developed for Immune Effector Cell-Associated HematoToxicity (ICAHT). In this multicenter, observational study, we applied the grading system to a large real-world cohort of 549 patients treated with BCMA- or CD19-directed CAR-T for refractory B-cell malignancies (112 multiple myeloma [MM], 334 large B-cell lymphoma [LBCL], 103 mantle cell lymphoma [MCL]) and examined the clinical sequelae of severe (\u22653\u00b0) ICAHT. The ICAHT grading was strongly associated with the cumulative duration of severe neutropenia (r\u00a0=\u00a00.92, P\u00a0&amp;lt; .0001), the presence of multilineage cytopenias, and the use of platelet and red blood cell transfusions. We noted an increased rate of severe ICAHT in patients with MCL vs those with LBCL and MM (28% vs 23% vs 15%). Severe ICAHT was associated with a higher rate of severe infections (49% vs 13%, P\u00a0&amp;lt; .0001), increased nonrelapse mortality (14% vs 4%, P\u00a0&amp;lt; .0001), and inferior survival outcomes (1-year progression-free survival: 35% vs 51%, 1-year overall survival: 52% vs 73%, both P\u00a0&amp;lt; .0001). Importantly, the ICAHT grading demonstrated superior capacity to predict severe infections compared with the CTCAE grading (c-index 0.73 vs 0.55, P\u00a0&amp;lt; .0001 vs nonsignificant). Taken together, these data highlight the clinical relevance of the novel grading system and support the reporting of ICAHT severity in clinical trials evaluating CAR-T therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011767","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T17:58:02Z","timestamp":1704477482000},"page":"1857-1868","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":88,"title":["Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"first","affiliation":[{"name":"1Department of Medicine III \u2013 Hematology\/Oncology, University Hospital, LMU Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany"},{"name":"3German Cancer Consortium (DKTK), Munich and Berlin Sites, and German Cancer Research Center, Heidelberg, Germany"},{"name":"4Adult BMT and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Vall d\u2019Hebron Institute of Oncology, University Hospital Vall d\u2019Hebron and Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Lyon Sud Hospital, Claude Bernard University Lyon 1, INSERM 1052, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-098X","authenticated-orcid":false,"given":"Radhika","family":"Bansal","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[{"name":"3German Cancer Consortium (DKTK), Munich and Berlin Sites, and German Cancer Research Center, Heidelberg, Germany"},{"name":"9Department of Hematology, Oncology and Tumorimmunology, Charit\u00e9 \u2013 Berlin University Medicine, Corporate Member of Free University of Berlin and Humboldt University, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-5839","authenticated-orcid":false,"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7280","authenticated-orcid":false,"given":"Veit L.","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"1Department of Medicine III \u2013 Hematology\/Oncology, University Hospital, LMU Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Vall d\u2019Hebron Institute of Oncology, University Hospital Vall d\u2019Hebron and Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[{"name":"6Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"1Department of Medicine III \u2013 Hematology\/Oncology, University Hospital, LMU Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany"},{"name":"3German Cancer Consortium (DKTK), Munich and Berlin Sites, and German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"issue":"7","key":"2024042313404024500_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for Large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024042313404024500_bib2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"10299","key":"2024042313404024500_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"2024042313404024500_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024042313404024500_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024042313404024500_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"2024042313404024500_bib7","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2024042313404024500_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024042313404024500_bib9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2024042313404024500_bib10","first-page":"2460","article-title":"How I treat Cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2024042313404024500_bib11","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024042313404024500_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2024042313404024500_bib13","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024042313404024500_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2024042313404024500_bib15","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2024042313404024500_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12879-020-05755-4","article-title":"Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report","volume":"21","author":"Rejeski","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2024042313404024500_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024042313404024500_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"2024042313404024500_bib19","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"24","key":"2024042313404024500_bib20","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucelin relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024042313404024500_bib21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"30","key":"2024042313404024500_bib22","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024042313404024500_bib23","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","article-title":"An International survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"2024042313404024500_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.2023021305","article-title":"A\u00a0road map for navigating CAR T hematotoxicity","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"38","key":"2024042313404024500_bib25","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"4","key":"2024042313404024500_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024042313404024500_bib27","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2024042313404024500_bib28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024042313404024500_bib29","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"2024042313404024500_bib30","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A\u00a0real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2024042313404024500_bib31","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","article-title":"Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors","volume":"54","author":"Xia","year":"2022","journal-title":"Ann Med"},{"issue":"4","key":"2024042313404024500_bib32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2024042313404024500_bib33","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2024042313404024500_bib34","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"2024042313404024500_bib35","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Non-relapse mortality after CAR T-cell therapy for large B-cell lymphoma: A LYSA Study from the DESCAR-T Registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"2024042313404024500_bib36","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2023-187516","article-title":"Infections Drive Non-Relapse Mortality Following CAR-T Therapy across Disease Entities and CAR Products - a Meta-Analysis of Clinical Trials and Real-World Studies","volume":"142","author":"Cordas dos Santos","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"2024042313404024500_bib37","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1182\/blood-2022-167632","article-title":"Biphasic neutrophil recovery after CD19 CART in R\/R LBCL is associated with superior PFS\/OS, robust CAR T-cell expansion in relation to baseline tumor volume, and a decrease of systemic inflammation over time","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2024042313404024500_bib38","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T\u00a0cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024042313404024500_bib39","doi-asserted-by":"crossref","first-page":"e002303","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"2024042313404024500_bib40","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V100.12.3877","article-title":"Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"issue":"30","key":"2024042313404024500_bib41","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the Association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024042313404024500_bib42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024042313404024500_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Lievin","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2024042313404024500_bib44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"24","key":"2024042313404024500_bib45","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024042313404024500_bib46","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging Antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024042313404024500_bib47","first-page":"1722","article-title":"Teclistamab in relapsed or refractory multiple myeloma. reply","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10301","key":"2024042313404024500_bib48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1857\/2222913\/blooda_adv-2023-011767-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1857\/2222913\/blooda_adv-2023-011767-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:41:09Z","timestamp":1713865269000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1857\/506970\/Applying-the-EHA-EBMT-grading-for-ICAHT-after-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011767","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}